CHICAGO — For patients with advanced heart failure, an injection of autologous mononuclear cells into damaged myocardia missed the primary endpoint in the sham-controlled, randomized, blinded CardiAMP-HF trial, but there was a strong signal of benefit, supporting further assessment. The study had a hierarchical win-ratio design…
Leave a Comment Leave a Comment
